69 related articles for article (PubMed ID: 7122527)
41. Dopamine receptor stimulants in hypertension.
Clark BJ
Acta Med Scand Suppl; 1977; 606():95-100. PubMed ID: 268936
[No Abstract] [Full Text] [Related]
42. Prostacyclin is a key mediator of the vasodilator action of dopamine in humans.
Horton R; Nadler J; Manogian C; Lee F
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():753-6. PubMed ID: 2960185
[No Abstract] [Full Text] [Related]
43. [Hemodynamic study of nicergoline].
Pony JC; Bourdonnec C; Amelot J; Dallerac J; Daubert JC; Gouffault J
Ann Cardiol Angeiol (Paris); 1982; 31(1):67-70. PubMed ID: 7065627
[No Abstract] [Full Text] [Related]
44. Of mice and men: the extension of animal models to the clinical evaluation of new drugs.
Lemberger L
Clin Pharmacol Ther; 1986 Dec; 40(6):599-603. PubMed ID: 2877763
[No Abstract] [Full Text] [Related]
45. THE CIRCULATION IN EXPERIMENTAL NEUROGENIC HYPERTENSION.
Bing RJ; Thomas CB; Waples EC
J Clin Invest; 1945 Jul; 24(4):513-22. PubMed ID: 16695240
[No Abstract] [Full Text] [Related]
46. Involvement of central dopamine receptors in the hypotensive action of pergolide.
Jadhav AL; Willett RN; Sapru HN; Lokhandwala MF
Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):281-6. PubMed ID: 6664381
[TBL] [Abstract][Full Text] [Related]
47. Differential antagonism of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides.
Kohli JD; Glock D; Goldberg LI
Adv Biochem Psychopharmacol; 1982; 35():97-108. PubMed ID: 6756064
[No Abstract] [Full Text] [Related]
48. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
[TBL] [Abstract][Full Text] [Related]
49. Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
Barrett RJ; Lokhandwala MF
Eur J Pharmacol; 1983 Dec; 96(3-4):211-26. PubMed ID: 6676105
[TBL] [Abstract][Full Text] [Related]
50. Characterization of the neurogenic vasodilatation elicited by central dopamine receptor stimulation with pergolide.
Lokhandwala MF; Kivlighn SD; Jandhyala BS
J Pharmacol Exp Ther; 1984 Mar; 228(3):696-703. PubMed ID: 6707919
[TBL] [Abstract][Full Text] [Related]
51. Antihypertensive activity of LY141865, a selective presynaptic dopamine receptor agonist.
Hahn RA; MacDonald BR; Martin MA
J Pharmacol Exp Ther; 1983 Jan; 224(1):206-14. PubMed ID: 6848744
[No Abstract] [Full Text] [Related]
52. Dopaminergic inhibition of cardiac sympathetic nerve function by pergolide.
Barrett RJ; Lokhandwala MF
Eur J Pharmacol; 1982 Jan; 77(1):79-83. PubMed ID: 6277657
[TBL] [Abstract][Full Text] [Related]
53. Presynaptic dopamine receptor stimulation and the antihypertensive action of pergolide in experimental neurogenic hypertension.
Barrett RJ; Lokhandwala MF
Proc West Pharmacol Soc; 1982; 25():39-42. PubMed ID: 7122527
[No Abstract] [Full Text] [Related]
54. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists.
Cavero I; Massingham R; Lefèvere-Borg F
Life Sci; 1982 Sep; 31(11):1059-69. PubMed ID: 6755118
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
